Atossa: Buy Rating Reiterated as DMD and Oncology Pipeline Advances; $20 Price Target Unchanged
at www.tipranks.com (Wed, 3-Jun 2:15 PM)
ATOS Secures FDA Rare Pediatric Disease Designation, Unlocking Potential Value in McCune-Albright Syndrome Program
Market Chameleon (Mon, 4-May 9:22 AM)
